Destiny
Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDAfor XF-73 Dermal Gel for Treatment of Burn Wound Infections
Have Any Questions?
Let us help you
Want to keep up to date with our companies?
Subscribe to our newsletter and receive latest information on your favourite companies and JP Jenkins news.